Based on the provided sources, there is no explicit mention of the requirement to perform an electrocardiogram (ECG) or to review the results before prescribing treatment with lenvatinib. However, it is important to note that lenvatinib is associated with certain cardiovascular risks, and healthcare professionals should carefully evaluate the patient's cardiovascular status before initiating treatment [2].
The prescribing information for lenvatinib states that patients with a history of cardiovascular disease or those who are at an increased risk of developing cardiovascular complications should be closely monitored during treatment [2]. The FDA label also recommends monitoring blood pressure regularly and managing any hypertension that may arise during lenvatinib treatment [3]. Additionally, the drug patent watch website provides information on lenvatinib's adverse effects, including hypertension and cardiac disorders [1].
While an ECG is not explicitly mentioned as a mandatory requirement before prescribing lenvatinib, it is possible that healthcare professionals may choose to perform an ECG as part of the overall evaluation of a patient's cardiovascular health before initiating treatment. The decision to perform an ECG and review the results would depend on the individual patient's medical history, risk factors, and the healthcare professional's clinical judgment.
In summary, while the sources do not explicitly state that an ECG is mandatory before prescribing lenvatinib, it is important for healthcare professionals to evaluate a patient's cardiovascular status and closely monitor them during treatment, especially if they have a history of cardiovascular disease or are at an increased risk of developing cardiovascular complications.
Sources:
[1] Drug Patent Watch. Lenvatinib. Retrieved from: https://www.drugpatentwatch.com/p/tradename/LENVATINIB
[2] Lenvima Prescribing Information. Retrieved from: https://www.lenvima.com/-/media/Project/EISAI/Lenvima/PDF/prescribing-information.pdf
[3] FDA Label for Lenvima. Retrieved from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206947s007lbl.pdf